Accession Number:

ADA505213

Title:

Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab. Phase 2

Descriptive Note:

Annual rept. 27 Apr 2008-26 Apr 2009

Corporate Author:

SEATTLE UNIV WA

Personal Author(s):

• Disis, Mary L.

Report Date:

2009-05-01

Pagination or Media Count:

10.0

Abstract:

The primary purpose of this grant is to determine the relapse free survival benefit with locally advanced and stage IV HER2 positive breast cancer patients vaccinated with a HER2 ICD peptide-based vaccine while receiving maintenance trastuzumab. The scope of work includes a Phase II single arm study of a HER2 ICD peptide-based vaccine given concurrently with trastuzumab. Fourteen patients have been enrolled during the last reporting period. All adverse events reported for these fourteen subjects are of low grade. Patients have developed significant T cell immune responses to the vaccine as we as epitope spreading indicating a Type I immune response is being elicited.

Descriptors:

• *BREAST CANCER
• SURVIVAL(GENERAL)
• ADVERSE CONDITIONS
• RESPONSE(BIOLOGY)
• IMMUNITY
• CELLS(BIOLOGY)
• VACCINES
• PEPTIDES
• T LYMPHOCYTES

Subject Categories:

• Anatomy and Physiology
• Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE